Skip to main content Skip to footer
Algernon Health Inc
  • Home
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Medical & Scientific Advisors
  • Alzheimer’s
    • Overview
    • AD Clinics
    • Markets
    • Resources
  • Pipeline
    • Overview
    • NP-251 (Repirinast)
    • AP-188 (DMT)
  • Companies
    • Algernon NeuroScience
  • News & Media
    • News Releases
    • IR Calendar
    • Presentations
    • Videos/Articles
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEDAR
    • Governance
  • Contact

We are currently in the process of updating our web site to reflect the announced plans to change our company name from Algernon Pharmaceuticals to Algernon Health. Please visit again soon as these changes continue to take effect across the entire web site.

News Releases

Apr 09, 2020 8:30am EDT

Algernon Announces Regulatory Submission for Ifenprodil COVID-19 Human Trial in South Korea

Apr 08, 2020 8:30am EDT

Algernon Announces Positive Feedback from Health Canada for Ifenprodil COVID-19 Phase 2 Human Trial

Apr 02, 2020 8:30am EDT

Algernon Provides Update on Phase 2 Human Testing of Ifenprodil for COVID-19

Mar 30, 2020 8:30am EDT

Algernon Submits for Ethics Approval for Phase 2 IPF and Chronic Cough Study

Mar 24, 2020 8:30am EDT

Algernon Provides an Overview of its NP-120 (Ifenprodil) Program for COVID-19

Mar 23, 2020 8:30am EDT

Algernon Appoints U.S. Company for cGMP Manufacturing of NP-120 (Ifenprodil) for COVID-19 Clinical Trials

Mar 20, 2020 2:22pm EDT

Algernon Appoints Novotech as CRO For Phase 2 Coronavirus Ifenprodil Trial

Mar 19, 2020 8:30am EDT

Algernon to Support Planned Phase 2 Trial of Ifenprodil for Coronavirus

Mar 13, 2020 2:56pm EDT

Algernon Contacts Gates Foundation Regarding Funding for New Coronavirus Treatments

Mar 13, 2020 8:30am EDT

Algernon Announces Filing of U.S. FDA Pre-IND Meeting Request for Ifenprodil Coronavirus Trial, Expanded Access, and Emergency Use

  • Previous Pagearrow_back
  • Page 1…
  • …
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Page 20
  • Page 21
  • Page 22
  • Page 23
  • Next Pagearrow_forward
rss_feed News RSS
  • Visit us on Facebook

    Facebook

  • Visit us on Twitter

    Twitter

  • Visit us on LinkedIn

    LinkedIn

  • Email Alerts
©2025 Algernon Health Inc. All Rights Reserved.
Privacy Policy Sitemap